AsianFin — South Korean pharmaceutical giant Samsung Biologics announced plans to split its operations into two distinct entities: a contract manufacturing organization (CMO) and a research and development (R&D) holding company.
According to a regulatory filing, Samsung Biologics will retain its drug contract manufacturing operations, while spinning off its biosimilar development unit into a newly established R&D-focused holding company.
The move is aimed at sharpening the company’s strategic focus and enhancing the efficiency of its growing biopharmaceutical business.
Explore more exclusive insights at nextfin.ai.
